Associated Papers
RET germline mutations drive tumorigenesis but not tumor aggressiveness in MEN 2.
Machens A et al.
Endocrine, 2026
Calcitonin Thresholds for Prediction of Medullary Thyroid Carcinoma and its Clinical Response in MEN2A Gene Carriers.
Prete A et al.
The Journal of Clinical Endocrinology and Metabolism, 2026
Multi-center multi-omics integration predicts individualized prognosis in medullary thyroid carcinoma.
Zhou Y et al.
Nature Communications, 2026
Geospatial inheritance across the breath of the RET mutational landscape of multiple endocrine neoplasia 2A.
Machens A et al.
Endocrine, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Four decades of the RET gene: From discovery to tumor-agnostic therapy.
Takahashi M
Journal of the Formosan Medical Association = Taiwan Yi Zhi, 2025
Approach to the Patient: Hereditary Medullary Thyroid Carcinoma.
Shariq OA et al.
The Journal of Clinical Endocrinology and Metabolism, 2025
Medullary Thyroid Cancer Risk and Mortality in Carriers of Incidentally Identified MEN2A RET Variants.
West CE et al.
Jama Network Open, 2025
Circulating tumor DNA profiling for non-invasive genomic analysis in Indian lung cancer patients: A real-world experience.
Jha P et al.
The Journal of Liquid Biopsy, 2025
Prioritization of predisposition genes for familial non-medullary thyroid cancer by whole-genome sequencing.
Srivastava A et al.
European Journal of Endocrinology, 2025
An Analysis of Primary Hyperparathyroidism in Individuals Diagnosed with Multiple Endocrine Neoplasia Type 2.
Gheorghe AM et al.
Diseases (basel, Switzerland), 2025
Hereditary Medullary Thyroid Cancer: Genotype-Phenotype Correlation.
Frank-Raue K et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer, 2025
Surgical Treatment of Medullary Thyroid Cancer.
Machens A et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer, 2025
Fundamentals and recent advances in the evaluation and management of medullary thyroid carcinoma.
Gigliotti BJ et al.
Molecular and Cellular Endocrinology, 2024
Oncological features of sporadic vs. hereditary pediatric medullary thyroid cancer.
Machens A et al.
Endocrine, 2024
Genetic landscape of 482 thyroid carcinomas: analysis with the national datacenter for cancer genomic medicine in Japan.
Yamazaki H et al.
Endocrine, 2024
RET Alterations Differentiate Molecular Profile of Medullary Thyroid Cancer.
Prabhash K et al.
Jco Precision Oncology, 2024
RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions.
Hamidi S et al.
Annales D'endocrinologie, 2024
Does Genotype-Specific Phenotype in Patients with Multiple Endocrine Neoplasia Type 2 Occur as Current Guidelines Predict?
Binter T et al.
Cancers, 2024
Multiple endocrine neoplasia type 2: towards a risk-based approach integrating molecular and biomarker results.
Machens A et al.
Current Opinion in Oncology, 2024
Prevalence of the cancer-associated germline variants in Russian adults and long-living individuals: using the ACMG recommendations and computational interpreters for pathogenicity assessment.
Gusakova M et al.
Frontiers in Oncology, 2024
Unveiling new chapters in medullary thyroid carcinoma therapy: advances in molecular genetics and targeted treatment strategies.
Huai JX et al.
Frontiers in Endocrinology, 2024
A 4-Year-Old Boy with an Accidentally Detected Mutation in the RET Proto-Oncogene and Mutation in the Gene Encoding the Ryanodine Receptor1 (RyR1)-Case Report.
Mierzwa M et al.
Children (basel, Switzerland), 2023
Molecular Basis and Natural History of Medullary Thyroid Cancer: It is (Almost) All in the RET.
Sahakian N et al.
Cancers, 2023
Targeting the RET tyrosine kinase in neuroblastoma: A review and application of a novel selective drug design strategy.
Steen EA et al.
Biochemical Pharmacology, 2023
Medullary Thyroid Cancer: Updates and Challenges.
Gild ML et al.
Endocrine Reviews, 2023
The Changing Face of Multiple Endocrine Neoplasia 2A: From Symptom-Based to Preventative Medicine.
Machens A et al.
The Journal of Clinical Endocrinology and Metabolism, 2023
From Circulating Tumor Cells to Mirna: New Challenges in the Diagnosis and Prognosis of Medullary Thyroid Cancer.
Ricci C et al.
Cancers, 2023
Looking for RET alterations in thyroid cancer: clinical relevance, methodology and timing.
Elisei R et al.
Endocrine, 2023
Personalized Medicine in Medullary Thyroid Carcinoma: A Broad Review of Emerging Treatments.
Martins RS et al.
Journal of Personalized Medicine, 2023
Temporal trends in referrals of RET gene carriers for neck surgery to a tertiary surgical center in the era of international management guidelines.
Machens A et al.
Endocrine, 2023
Progress and challenges in RET-targeted cancer therapy.
Hu X et al.
Frontiers of Medicine, 2023
Low Frequency of Cancer-Predisposition Gene Mutations in Liver Transplant Candidates with Hepatocellular Carcinoma.
Horackova K et al.
Cancers, 2022
RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges.
Servetto A et al.
Biochimica Et Biophysica Acta. Reviews on Cancer, 2022
RET Proto-Oncogene-Not Such an Obvious Starting Point in Cancer Therapy.
Kucharczyk T et al.
Cancers, 2022
Novel Calcium-Binding Ablating Mutations Induce Constitutive RET Activity and Drive Tumorigenesis.
Tabata J et al.
Cancer Research, 2022
Sex differences in MEN 2A penetrance and expression according to parental inheritance.
Machens A et al.
European Journal of Endocrinology, 2022
RET receptor signaling: Function in development, metabolic disease, and cancer.
Takahashi M
Proceedings of the Japan Academy. Series B, Physical and Biological Sciences, 2022
Comprehensive Assessment of Indian Variations in the Druggable Kinome Landscape Highlights Distinct Insights at the Sequence, Structure and Pharmacogenomic Stratum.
Panda G et al.
Frontiers in Pharmacology, 2022
GLOBAL ENDOCRINOLOGY: Geographical variation in the profile of RET variants in patients with medullary thyroid cancer: a comprehensive review.
Maciel RMB et al.
European Journal of Endocrinology, 2021
Active Surveillance in RET Gene Carriers Belonging to Families with Multiple Endocrine Neoplasia.
Prete A et al.
Cancers, 2021
Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases.
Moccia M et al.
Scientific Reports, 2021
Exceptionality of Distant Metastasis in Node-Negative Hereditary and Sporadic Medullary Thyroid Cancer: Lessons Learned.
Machens A et al.
The Journal of Clinical Endocrinology and Metabolism, 2021
The importance of the RET gene in thyroid cancer and therapeutic implications.
Salvatore D et al.
Nature Reviews. Endocrinology, 2021
Lymph node metastasis in hereditary medullary thyroid cancer is independent of the underlying RET germline mutation.
Machens A et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2021
ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research.
Belli C et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2021
A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer.
Romei C et al.
International Journal of Molecular Sciences, 2021